Inventor
FEUERBACH DOMINIK
CH25 patents
⚠️ This page may combine multiple inventors who share the name “FEUERBACH DOMINIK”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
NOVARTIS AG
17 patentsUS7713977B2May 11, 2010
(1-aza-bicyclo[3.3.1]non-4-yl)-[5-(1H-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenerative disorders
NOVARTIS AG20 citations91
US7713976B2May 11, 2010
[(1H-indol-5-yl)-heteroaryloxy]-1-aza-bicylco[3.3.1]nonanes as cholinergic ligands of the n-AChR for the treatment of psychotic and neurodegenerative disorders
NOVARTIS AG19 citations91
US7579362B2Aug 25, 2009
Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonists
NOVARTIS AG17 citations91
US9475811B2Oct 25, 2016
1-aza-bicyclo[3.3.1]nonanes
NOVARTIS AG11 citations82
US11492402B2Nov 8, 2022
TREM2 stabilizing antibodies
NOVARTIS AG11 citations81
US8048885B2Nov 1, 2011
Organic compounds
NOVARTIS AG5 citations72
US9567343B2Feb 14, 2017
Aza-bicyloalkyl ethers and their use as alpha7-nachr agonists
NOVARTIS AG1 citations60
US12595306B2Apr 7, 2026
TREM2 stabilizing antibodies
NOVARTIS AG0 citations58
US12595305B2Apr 7, 2026
TREM2 stabilizing antibodies
NOVARTIS AG0 citations58
US12215387B2Feb 4, 2025
Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
NOVARTIS AG0 citations58
US11359241B2Jun 14, 2022
Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
NOVARTIS AG0 citations58
US9828642B2Nov 28, 2017
Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
NOVARTIS AG1 citations58
US11096916B2Aug 24, 2021
Use of nicotinic acetylcholine receptor alpha 7 activators
NOVARTIS AG0 citations57
US11311525B2Apr 26, 2022
Use of alpha 7 nicotinic acetylcholine receptor agonists
NOVARTIS AG0 citations54
US9657010B2May 23, 2017
Substituted quinuclidines as alpha 7-nicotinic acetylcholine receptor activity modulators
NOVARTIS AG0 citations51
US9206181B2Dec 8, 2015
1-aza-bicyclo[3.3.1] non-4-yl)-[5-(1H-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-AChR for the treatment of psychotic and neurodegenerative disorders
NOVARTIS AG0 citations51
US9849117B2Dec 26, 2017
Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists
NOVARTIS AG0 citations50
FEUERBACH DOMINIK
6 patentsUS8933090B2Jan 13, 2015
1-aza-bicyclo[3.3.1]nonanes
FEUERBACH DOMINIK11 citations82
US8609662B2Dec 17, 2013
3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha. 7-nachr ligands for the treatment of CNS diseases
FEUERBACH DOMINIK13 citations82
US8173667B2May 8, 2012
1-aza-bicycloalkyl derivatives
FEUERBACH DOMINIK10 citations79
US9012451B2Apr 21, 2015
Aza-bicycloalkyl ethers and their use as ALPHA7-nachr agonists
FEUERBACH DOMINIK1 citations61
US8236803B2Aug 7, 2012
Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonists
FEUERBACH DOMINIK1 citations61
US8637517B2Jan 28, 2014
Organic compounds
FEUERBACH DOMINIK3 citations60